APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Sexual Dysfunction

Compare research editions
View pricing & licenses

Selected research

Industry Research

Drugs for Sexual Dysfunction Industry Research Report 2026

28 December 2025133 pages

Choose your research edition.

Industry ResearchDrugs for Sexual Dysfunction Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Sexual Dysfunction Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drugs for Sexual Dysfunction Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Sexual Dysfunction Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Sexual Dysfunction Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Drugs for Sexual Dysfunction market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Drugs for Sexual Dysfunction is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Drugs for Sexual Dysfunction is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Drugs for Sexual Dysfunction include Boston Scientific Corporation, CSBio, Dong-A ST, General Factory, Hims, Lilly ICOS LLC, Lupin, Meda Pharmaceuticals and Menarini Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Drugs for Sexual Dysfunction market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Drugs for Sexual Dysfunction Market by Company

Boston Scientific Corporation

CSBio

Dong-A ST

General Factory

Hims

Lilly ICOS LLC

Lupin

Meda Pharmaceuticals

Menarini Group

Metuchen Pharma

SK Chemicals.

Vivus, Inc.

Bayer AG

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Pfizer Inc

Lilly

Sanofi

Teva Pharmaceutical Industries Ltd.

Drugs for Sexual Dysfunction Segment by Type

Vardenafil (Levitra, Staxyn)

Tadalafil (Cialis)

Udenafil (Zydena)

Sildenafil (Viagra)

Others

Drugs for Sexual Dysfunction Segment by Application

Retail Pharmacies

Online Pharmacies

Hospitals

Clinics

Drugs for Sexual Dysfunction Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Sexual Dysfunction market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Sexual Dysfunction and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Sexual Dysfunction.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Drugs for Sexual Dysfunction manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Drugs for Sexual Dysfunction by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Drugs for Sexual Dysfunction in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for Sexual Dysfunction Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Drugs for Sexual Dysfunction Sales (Units) of Manufacturers (2021-2026) Table 7. Global Drugs for Sexual Dysfunction Sales Market Share by Manufacturers (2021-2026) Table 8. Global Drugs for Sexual Dysfunction Revenue of Manufacturers (2021-2026) Table 9. Global Drugs for Sexual Dysfunction Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Drugs for Sexual Dysfunction Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Drugs for Sexual Dysfunction Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Drugs for Sexual Dysfunction, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Drugs for Sexual Dysfunction, Product Type & Application Table 14. Global Drugs for Sexual Dysfunction Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Drugs for Sexual Dysfunction by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Boston Scientific Corporation Company Information Table 19. Boston Scientific Corporation Business Overview Table 20. Boston Scientific Corporation Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Boston Scientific Corporation Drugs for Sexual Dysfunction Product Portfolio Table 22. Boston Scientific Corporation Recent Developments Table 23. CSBio Company Information Table 24. CSBio Business Overview Table 25. CSBio Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. CSBio Drugs for Sexual Dysfunction Product Portfolio Table 27. CSBio Recent Developments Table 28. Dong-A ST Company Information Table 29. Dong-A ST Business Overview Table 30. Dong-A ST Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Dong-A ST Drugs for Sexual Dysfunction Product Portfolio Table 32. Dong-A ST Recent Developments Table 33. General Factory Company Information Table 34. General Factory Business Overview Table 35. General Factory Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. General Factory Drugs for Sexual Dysfunction Product Portfolio Table 37. General Factory Recent Developments Table 38. Hims Company Information Table 39. Hims Business Overview Table 40. Hims Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Hims Drugs for Sexual Dysfunction Product Portfolio Table 42. Hims Recent Developments Table 43. Lilly ICOS LLC Company Information Table 44. Lilly ICOS LLC Business Overview Table 45. Lilly ICOS LLC Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Lilly ICOS LLC Drugs for Sexual Dysfunction Product Portfolio Table 47. Lilly ICOS LLC Recent Developments Table 48. Lupin Company Information Table 49. Lupin Business Overview Table 50. Lupin Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lupin Drugs for Sexual Dysfunction Product Portfolio Table 52. Lupin Recent Developments Table 53. Meda Pharmaceuticals Company Information Table 54. Meda Pharmaceuticals Business Overview Table 55. Meda Pharmaceuticals Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Meda Pharmaceuticals Drugs for Sexual Dysfunction Product Portfolio Table 57. Meda Pharmaceuticals Recent Developments Table 58. Menarini Group Company Information Table 59. Menarini Group Business Overview Table 60. Menarini Group Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Menarini Group Drugs for Sexual Dysfunction Product Portfolio Table 62. Menarini Group Recent Developments Table 63. Metuchen Pharma Company Information Table 64. Metuchen Pharma Business Overview Table 65. Metuchen Pharma Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Metuchen Pharma Drugs for Sexual Dysfunction Product Portfolio Table 67. Metuchen Pharma Recent Developments Table 68. SK Chemicals. Company Information Table 69. SK Chemicals. Business Overview Table 70. SK Chemicals. Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. SK Chemicals. Drugs for Sexual Dysfunction Product Portfolio Table 72. SK Chemicals. Recent Developments Table 73. Vivus, Inc. Company Information Table 74. Vivus, Inc. Business Overview Table 75. Vivus, Inc. Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Vivus, Inc. Drugs for Sexual Dysfunction Product Portfolio Table 77. Vivus, Inc. Recent Developments Table 78. Bayer AG Company Information Table 79. Bayer AG Business Overview Table 80. Bayer AG Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bayer AG Drugs for Sexual Dysfunction Product Portfolio Table 82. Bayer AG Recent Developments Table 83. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Company Information Table 84. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Business Overview Table 85. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Product Portfolio Table 87. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Recent Developments Table 88. Pfizer Inc Company Information Table 89. Pfizer Inc Business Overview Table 90. Pfizer Inc Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Pfizer Inc Drugs for Sexual Dysfunction Product Portfolio Table 92. Pfizer Inc Recent Developments Table 93. Lilly Company Information Table 94. Lilly Business Overview Table 95. Lilly Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lilly Drugs for Sexual Dysfunction Product Portfolio Table 97. Lilly Recent Developments Table 98. Sanofi Company Information Table 99. Sanofi Business Overview Table 100. Sanofi Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Sanofi Drugs for Sexual Dysfunction Product Portfolio Table 102. Sanofi Recent Developments Table 103. Teva Pharmaceutical Industries Ltd. Company Information Table 104. Teva Pharmaceutical Industries Ltd. Business Overview Table 105. Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Product Portfolio Table 107. Teva Pharmaceutical Industries Ltd. Recent Developments Table 108. Global Drugs for Sexual Dysfunction Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Drugs for Sexual Dysfunction Sales by Region (2021-2026) & (Units) Table 110. Global Drugs for Sexual Dysfunction Sales Market Share by Region (2021-2026) Table 111. Global Drugs for Sexual Dysfunction Sales by Region (2027-2032) & (Units) Table 112. Global Drugs for Sexual Dysfunction Sales Market Share by Region (2027-2032) Table 113. Global Drugs for Sexual Dysfunction Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Drugs for Sexual Dysfunction Revenue Market Share by Region (2021-2026) Table 115. Global Drugs for Sexual Dysfunction Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Drugs for Sexual Dysfunction Revenue Market Share by Region (2027-2032) Table 117. North America Drugs for Sexual Dysfunction Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 119. North America Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 120. North America Drugs for Sexual Dysfunction Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Drugs for Sexual Dysfunction Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Drugs for Sexual Dysfunction Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 124. Europe Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 125. Europe Drugs for Sexual Dysfunction Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Drugs for Sexual Dysfunction Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Drugs for Sexual Dysfunction Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 129. Asia Pacific Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 130. Asia Pacific Drugs for Sexual Dysfunction Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Drugs for Sexual Dysfunction Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Drugs for Sexual Dysfunction Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 134. South America Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 135. South America Drugs for Sexual Dysfunction Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Drugs for Sexual Dysfunction Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Drugs for Sexual Dysfunction Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 139. Middle East and Africa Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 140. Middle East and Africa Drugs for Sexual Dysfunction Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Drugs for Sexual Dysfunction Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Drugs for Sexual Dysfunction Sales by Type (2021-2026) & (Units) Table 143. Global Drugs for Sexual Dysfunction Sales by Type (2027-2032) & (Units) Table 144. Global Drugs for Sexual Dysfunction Sales Market Share by Type (2021-2026) Table 145. Global Drugs for Sexual Dysfunction Sales Market Share by Type (2027-2032) Table 146. Global Drugs for Sexual Dysfunction Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Drugs for Sexual Dysfunction Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Drugs for Sexual Dysfunction Revenue Market Share by Type (2021-2026) Table 149. Global Drugs for Sexual Dysfunction Revenue Market Share by Type (2027-2032) Table 150. Global Drugs for Sexual Dysfunction Price by Type (2021-2026) & (US$/Unit) Table 151. Global Drugs for Sexual Dysfunction Price by Type (2027-2032) & (US$/Unit) Table 152. Global Drugs for Sexual Dysfunction Sales by Application (2021-2026) & (Units) Table 153. Global Drugs for Sexual Dysfunction Sales by Application (2027-2032) & (Units) Table 154. Global Drugs for Sexual Dysfunction Sales Market Share by Application (2021-2026) Table 155. Global Drugs for Sexual Dysfunction Sales Market Share by Application (2027-2032) Table 156. Global Drugs for Sexual Dysfunction Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Drugs for Sexual Dysfunction Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Drugs for Sexual Dysfunction Revenue Market Share by Application (2021-2026) Table 159. Global Drugs for Sexual Dysfunction Revenue Market Share by Application (2027-2032) Table 160. Global Drugs for Sexual Dysfunction Price by Application (2021-2026) & (US$/Unit) Table 161. Global Drugs for Sexual Dysfunction Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Drugs for Sexual Dysfunction Distributors List Table 165. Drugs for Sexual Dysfunction Customers List Table 166. Drugs for Sexual Dysfunction Industry Trends Table 167. Drugs for Sexual Dysfunction Industry Drivers Table 168. Drugs for Sexual Dysfunction Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Drugs for Sexual Dysfunction Product Image Figure 5. Global Drugs for Sexual Dysfunction Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Drugs for Sexual Dysfunction Market Size (2021-2032) & (US$ Million) Figure 7. Global Drugs for Sexual Dysfunction Sales (2021-2032) & (Units) Figure 8. Global Drugs for Sexual Dysfunction Average Price (US$/Unit) & (2021-2032) Figure 9. Vardenafil (Levitra, Staxyn) Product Image Figure 10. Tadalafil (Cialis) Product Image Figure 11. Udenafil (Zydena) Product Image Figure 12. Sildenafil (Viagra) Product Image Figure 13. Others Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Online Pharmacies Product Image Figure 16. Hospitals Product Image Figure 17. Clinics Product Image Figure 18. Global Drugs for Sexual Dysfunction Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Drugs for Sexual Dysfunction, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Drugs for Sexual Dysfunction Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Drugs for Sexual Dysfunction Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Drugs for Sexual Dysfunction Sales by Region in 2025 Figure 24. Global Drugs for Sexual Dysfunction Revenue by Region in 2025 Figure 25. North America Drugs for Sexual Dysfunction Market Size by Country in 2025 Figure 26. North America Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2032) Figure 27. North America Drugs for Sexual Dysfunction Revenue Market Share by Country (2021-2032) Figure 28. United States Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Drugs for Sexual Dysfunction Market Size by Country in 2025 Figure 32. Europe Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2032) Figure 33. Europe Drugs for Sexual Dysfunction Revenue Market Share by Country (2021-2032) Figure 34. Germany Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Drugs for Sexual Dysfunction Market Size by Country in 2025 Figure 45. Asia Pacific Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Drugs for Sexual Dysfunction Revenue Market Share by Country (2021-2032) Figure 47. China Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Drugs for Sexual Dysfunction Market Size by Country in 2025 Figure 56. South America Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2032) Figure 57. South America Drugs for Sexual Dysfunction Revenue Market Share by Country (2021-2032) Figure 58. Brazil Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Colombia Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Drugs for Sexual Dysfunction Market Size by Country in 2025 Figure 63. Middle East and Africa Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Drugs for Sexual Dysfunction Revenue Market Share by Country (2021-2032) Figure 65. Egypt Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Drugs for Sexual Dysfunction Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Drugs for Sexual Dysfunction Sales Market Share by Type (2021-2032) Figure 71. Global Drugs for Sexual Dysfunction Revenue Market Share by Type (2021-2032) Figure 72. Global Drugs for Sexual Dysfunction Price (US$/Unit) by Type (2021-2032) Figure 73. Global Drugs for Sexual Dysfunction Sales Market Share by Application (2021-2032) Figure 74. Global Drugs for Sexual Dysfunction Revenue Market Share by Application (2021-2032) Figure 75. Global Drugs for Sexual Dysfunction Price (US$/Unit) by Application (2021-2032) Figure 76. Drugs for Sexual Dysfunction Value Chain Figure 77. Drugs for Sexual Dysfunction Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Drugs for Sexual Dysfunction Industry Opportunities and Challenges

Scope & coverage.

Types
  • Vardenafil (Levitra, Staxyn)
  • Tadalafil (Cialis)
  • Udenafil (Zydena)
  • Sildenafil (Viagra)
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospitals
  • Clinics
Companies covered
  • Boston Scientific Corporation
  • CSBio
  • Dong-A ST
  • General Factory
  • Hims
  • Lilly ICOS LLC
  • Lupin
  • Meda Pharmaceuticals
  • Menarini Group
  • Metuchen Pharma
  • SK Chemicals.
  • Vivus, Inc.
  • Bayer AG
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Pfizer Inc
  • Lilly
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Drugs for Sexual Dysfunction Market Size (2021-2032)
  4. 2.2.2 Global Drugs for Sexual Dysfunction Sales (2021-2032)
  5. 2.2.3 Global Drugs for Sexual Dysfunction Market Average Price (2021-2032)
  6. 2.3 Drugs for Sexual Dysfunction by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Vardenafil (Levitra, Staxyn)
  9. 2.3.3 Tadalafil (Cialis)
  10. 2.3.4 Udenafil (Zydena)
  11. 2.3.5 Sildenafil (Viagra)
  12. 2.3.6 Others
  13. 2.4 Drugs for Sexual Dysfunction by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Retail Pharmacies
  16. 2.4.3 Online Pharmacies
  17. 2.4.4 Hospitals
  18. 2.4.5 Clinics
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Drugs for Sexual Dysfunction Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Drugs for Sexual Dysfunction Sales (Units) of Manufacturers (2021-2026)
  3. 3.3 Global Drugs for Sexual Dysfunction Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Drugs for Sexual Dysfunction Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Drugs for Sexual Dysfunction Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Drugs for Sexual Dysfunction, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Drugs for Sexual Dysfunction, Product Type & Application
  8. 3.8 Global Manufacturers of Drugs for Sexual Dysfunction, Established Date
  9. 3.9 Global Drugs for Sexual Dysfunction Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Boston Scientific Corporation
  2. 4.1.1 Boston Scientific Corporation Company Information
  3. 4.1.2 Boston Scientific Corporation Business Overview
  4. 4.1.3 Boston Scientific Corporation Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Boston Scientific Corporation Drugs for Sexual Dysfunction Product Portfolio
  6. 4.1.5 Boston Scientific Corporation Recent Developments
  7. 4.2 CSBio
  8. 4.2.1 CSBio Company Information
  9. 4.2.2 CSBio Business Overview
  10. 4.2.3 CSBio Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 CSBio Drugs for Sexual Dysfunction Product Portfolio
  12. 4.2.5 CSBio Recent Developments
  13. 4.3 Dong-A ST
  14. 4.3.1 Dong-A ST Company Information
  15. 4.3.2 Dong-A ST Business Overview
  16. 4.3.3 Dong-A ST Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Dong-A ST Drugs for Sexual Dysfunction Product Portfolio
  18. 4.3.5 Dong-A ST Recent Developments
  19. 4.4 General Factory
  20. 4.4.1 General Factory Company Information
  21. 4.4.2 General Factory Business Overview
  22. 4.4.3 General Factory Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 General Factory Drugs for Sexual Dysfunction Product Portfolio
  24. 4.4.5 General Factory Recent Developments
  25. 4.5 Hims
  26. 4.5.1 Hims Company Information
  27. 4.5.2 Hims Business Overview
  28. 4.5.3 Hims Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Hims Drugs for Sexual Dysfunction Product Portfolio
  30. 4.5.5 Hims Recent Developments
  31. 4.6 Lilly ICOS LLC
  32. 4.6.1 Lilly ICOS LLC Company Information
  33. 4.6.2 Lilly ICOS LLC Business Overview
  34. 4.6.3 Lilly ICOS LLC Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Lilly ICOS LLC Drugs for Sexual Dysfunction Product Portfolio
  36. 4.6.5 Lilly ICOS LLC Recent Developments
  37. 4.7 Lupin
  38. 4.7.1 Lupin Company Information
  39. 4.7.2 Lupin Business Overview
  40. 4.7.3 Lupin Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lupin Drugs for Sexual Dysfunction Product Portfolio
  42. 4.7.5 Lupin Recent Developments
  43. 4.8 Meda Pharmaceuticals
  44. 4.8.1 Meda Pharmaceuticals Company Information
  45. 4.8.2 Meda Pharmaceuticals Business Overview
  46. 4.8.3 Meda Pharmaceuticals Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Meda Pharmaceuticals Drugs for Sexual Dysfunction Product Portfolio
  48. 4.8.5 Meda Pharmaceuticals Recent Developments
  49. 4.9 Menarini Group
  50. 4.9.1 Menarini Group Company Information
  51. 4.9.2 Menarini Group Business Overview
  52. 4.9.3 Menarini Group Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Menarini Group Drugs for Sexual Dysfunction Product Portfolio
  54. 4.9.5 Menarini Group Recent Developments
  55. 4.10 Metuchen Pharma
  56. 4.10.1 Metuchen Pharma Company Information
  57. 4.10.2 Metuchen Pharma Business Overview
  58. 4.10.3 Metuchen Pharma Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Metuchen Pharma Drugs for Sexual Dysfunction Product Portfolio
  60. 4.10.5 Metuchen Pharma Recent Developments
  61. 4.11 SK Chemicals.
  62. 4.11.1 SK Chemicals. Company Information
  63. 4.11.2 SK Chemicals. Business Overview
  64. 4.11.3 SK Chemicals. Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 SK Chemicals. Drugs for Sexual Dysfunction Product Portfolio
  66. 4.11.5 SK Chemicals. Recent Developments
  67. 4.12 Vivus, Inc.
  68. 4.12.1 Vivus, Inc. Company Information
  69. 4.12.2 Vivus, Inc. Business Overview
  70. 4.12.3 Vivus, Inc. Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Vivus, Inc. Drugs for Sexual Dysfunction Product Portfolio
  72. 4.12.5 Vivus, Inc. Recent Developments
  73. 4.13 Bayer AG
  74. 4.13.1 Bayer AG Company Information
  75. 4.13.2 Bayer AG Business Overview
  76. 4.13.3 Bayer AG Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Bayer AG Drugs for Sexual Dysfunction Product Portfolio
  78. 4.13.5 Bayer AG Recent Developments
  79. 4.14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  80. 4.14.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Company Information
  81. 4.14.2 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Business Overview
  82. 4.14.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Product Portfolio
  84. 4.14.5 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Recent Developments
  85. 4.15 Pfizer Inc
  86. 4.15.1 Pfizer Inc Company Information
  87. 4.15.2 Pfizer Inc Business Overview
  88. 4.15.3 Pfizer Inc Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Pfizer Inc Drugs for Sexual Dysfunction Product Portfolio
  90. 4.15.5 Pfizer Inc Recent Developments
  91. 4.16 Lilly
  92. 4.16.1 Lilly Company Information
  93. 4.16.2 Lilly Business Overview
  94. 4.16.3 Lilly Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Lilly Drugs for Sexual Dysfunction Product Portfolio
  96. 4.16.5 Lilly Recent Developments
  97. 4.17 Sanofi
  98. 4.17.1 Sanofi Company Information
  99. 4.17.2 Sanofi Business Overview
  100. 4.17.3 Sanofi Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Sanofi Drugs for Sexual Dysfunction Product Portfolio
  102. 4.17.5 Sanofi Recent Developments
  103. 4.18 Teva Pharmaceutical Industries Ltd.
  104. 4.18.1 Teva Pharmaceutical Industries Ltd. Company Information
  105. 4.18.2 Teva Pharmaceutical Industries Ltd. Business Overview
  106. 4.18.3 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Product Portfolio
  108. 4.18.5 Teva Pharmaceutical Industries Ltd. Recent Developments
5 Global Drugs for Sexual Dysfunction Market Scenario by Region
  1. 5.1 Global Drugs for Sexual Dysfunction Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Drugs for Sexual Dysfunction Sales by Region: 2021-2032
  3. 5.2.1 Global Drugs for Sexual Dysfunction Sales by Region: 2021-2026
  4. 5.2.2 Global Drugs for Sexual Dysfunction Sales by Region: 2027-2032
  5. 5.3 Global Drugs for Sexual Dysfunction Revenue by Region: 2021-2032
  6. 5.3.1 Global Drugs for Sexual Dysfunction Revenue by Region: 2021-2026
  7. 5.3.2 Global Drugs for Sexual Dysfunction Revenue by Region: 2027-2032
  8. 5.4 North America Drugs for Sexual Dysfunction Market Facts & Figures by Country
  9. 5.4.1 North America Drugs for Sexual Dysfunction Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  11. 5.4.3 North America Drugs for Sexual Dysfunction Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Drugs for Sexual Dysfunction Market Facts & Figures by Country
  16. 5.5.1 Europe Drugs for Sexual Dysfunction Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  18. 5.5.3 Europe Drugs for Sexual Dysfunction Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Drugs for Sexual Dysfunction Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Drugs for Sexual Dysfunction Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Drugs for Sexual Dysfunction Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Drugs for Sexual Dysfunction Market Facts & Figures by Country
  41. 5.7.1 South America Drugs for Sexual Dysfunction Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  43. 5.7.3 South America Drugs for Sexual Dysfunction Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Drugs for Sexual Dysfunction Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Drugs for Sexual Dysfunction Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Drugs for Sexual Dysfunction Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Drugs for Sexual Dysfunction Sales by Type (2021-2032)
  2. 6.1.1 Global Drugs for Sexual Dysfunction Sales by Type (2021-2032) & (Units)
  3. 6.1.2 Global Drugs for Sexual Dysfunction Sales Market Share by Type (2021-2032)
  4. 6.2 Global Drugs for Sexual Dysfunction Revenue by Type (2021-2032)
  5. 6.2.1 Global Drugs for Sexual Dysfunction Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Drugs for Sexual Dysfunction Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Drugs for Sexual Dysfunction Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Drugs for Sexual Dysfunction Sales by Application (2021-2032)
  2. 7.1.1 Global Drugs for Sexual Dysfunction Sales by Application (2021-2032) & (Units)
  3. 7.1.2 Global Drugs for Sexual Dysfunction Sales Market Share by Application (2021-2032)
  4. 7.2 Global Drugs for Sexual Dysfunction Revenue by Application (2021-2032)
  5. 7.2.1 Global Drugs for Sexual Dysfunction Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Drugs for Sexual Dysfunction Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Drugs for Sexual Dysfunction Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Drugs for Sexual Dysfunction Value Chain Analysis
  2. 8.1.1 Drugs for Sexual Dysfunction Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Drugs for Sexual Dysfunction Production Mode & Process
  5. 8.2 Drugs for Sexual Dysfunction Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Drugs for Sexual Dysfunction Distributors
  8. 8.2.3 Drugs for Sexual Dysfunction Customers
9 Global Drugs for Sexual Dysfunction Analyzing Market Dynamics
  1. 9.1 Drugs for Sexual Dysfunction Industry Trends
  2. 9.2 Drugs for Sexual Dysfunction Industry Drivers
  3. 9.3 Drugs for Sexual Dysfunction Industry Opportunities and Challenges
  4. 9.4 Drugs for Sexual Dysfunction Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst